share_log

Traws Pharma To Unveil Next-Gen Oral Antivirals for Bird Flu And COVID-19 At March 31 Investor Event

Benzinga ·  Mar 26 11:33

Event to highlight the differentiated features of Traws oral small molecule product candidates:

  • Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird Flu
  • Ratutrelvir, a main protease inhibitor, to be used without ritonavir, for COVID-19
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 356

Recommended

Write a comment